Page 220 - IJB-9-2

International Journal of Bioprinting Three-dimensional bioprinting in toxicological research

Consent for publication https://doi.org/10.1016/j.actbio.2017.05.025

Not applicable. 11. Sun D, Gao W, Hu H, et al., 2022, Why 90% of clinical drug
development fails and how to improve it? Acta Pharm Sin B,
Availability of data 12: 3049–3062.

Not applicable. https://doi.org/10.1016/j.apsb.2022.02.002
12. Smith DA, Beaumont K, Maurer TS, et al., 2019, Clearance
References in drug design. J Med Chem, 62: 2245–2255.

1. Li AP, 2001, Screening for human ADME/Tox drug https://doi.org/10.1021/acs.jmedchem.8b01263
properties in drug discovery. Drug Discov Today, 6: 357–366.
13. Phua J, Lee KH, 2008, Liver support devices. Curr Opin Crit
https://doi.org/10.1016/s1359-6446(01)01712-3 Care, 14: 208–215.
2. Wishart DS, 2016, Emerging applications of metabolomics https://doi.org/10.1097/MCC.0b013e3282f70057
in drug discovery and precision medicine. Nat Rev Drug 14. Zhang X, Jiang T, Chen D, et al., 2020, Three-dimensional
Discov, 15: 473–484. liver models: State of the art and their application for
https://doi.org/10.1038/nrd.2016.32 hepatotoxicity evaluation. Crit Rev Toxicol, 50: 279–309.
3. Hingorani AD, Kuan V, Finan C, et al., 2019, Improving https://doi.org/10.1080/10408444.2020.1756219
the odds of drug development success through human 15. Roden M, 2016, The liver in focus. Diabetologia, 59: 1095–1097.
genomics: Modelling study. Sci Rep, 9: 18911.
https://doi.org/10.1007/s00125-016-3911-x
https://doi.org/10.1038/s41598-019-54849-w
16. Lorente S, Hautefeuille M, Sanchez-Cedillo A, 2020, The
4. Serras AS, Rodrigues JS, Cipriano M, et al., 2021, A critical liver, a functionalized vascular structure. Sci Rep, 10: 16194.
perspective on 3D liver models for drug metabolism and
toxicology studies. Front Cell Dev Biol, 9: 626805. https://doi.org/10.1038/s41598-020-73208-8
https://doi.org/10.3389/fcell.2021.626805 17. Shin D, Monga SP, 2013, Cellular and molecular basis of
liver development. Compr Physiol, 3(2): 799–815.
5. Park Y, Huh KM, Kang SW, 2021, Applications of
biomaterials in 3D cell culture and contributions of 3D cell https://doi.org/10.1002/cphy.c120022
culture to drug development and basic biomedical research. 18. Stockert RJ, Wolkoff AW, 2001, Cellular and molecular
Int J Mol Sci, 22: 2491. biology of the liver. Curr Opin Gastroenterol, 17: 205–210.
https://doi.org/10.3390/ijms22052491 https://doi.org/10.1097/00001574-200105000-00003
6. Ma C, Peng Y, Li H, et al., 2021, Organ-on-a-chip: A new 19. Popper H, 1956, Correlation of liver structure and function.
paradigm for drug development. Trends Pharmacol Sci, Q Bull Northwest Univ Med Sch, 30: 325–330.
42: 119–133.
http://www.ncbi.nlm.nih.gov/pubmed/13408428
https://doi.org/10.1016/j.tips.2020.11.009
20. Michalopoulos GK, Bhushan B, 2021, Liver regeneration:
7. Saltsman JA, Hammond WJ, Narayan NJ, et al., 2020, A biological and pathological mechanisms and implications.
human organoid model of aggressive hepatoblastoma for Nat Rev Gastroenterol Hepatol, 18: 40–55.
disease modeling and drug testing. Cancers (Basel), 12: 2668.
https://doi.org/10.1038/s41575-020-0342-4
https://doi.org/10.3390/cancers12092668
21. Poyck PP, Hoekstra R, Chhatta A, et al., 2007, Time-
8. Takahashi T, 2019, Organoids for drug discovery and related analysis of metabolic liver functions, cellular
personalized medicine. Annu Rev Pharmacol Toxicol, morphology, and gene expression of hepatocytes cultured
59: 447–462. in the bioartificial liver of the academic medical center in
https://doi.org/10.1146/annurev-pharmtox-010818-021108 Amsterdam (AMC-BAL). Tissue Eng, 13: 1235–1246.
9. Devarasetty M, Mazzocchi AR, Skardal A, 2018, Applications https://doi.org/10.1089/ten.2006.0343
of bioengineered 3D tissue and tumor organoids in drug 22. Pahlavan PS, Feldmann RE Jr., Zavos C, et al., 2006,
development and precision medicine: Current and future. Prometheus’ challenge: molecular, cellular and systemic
BioDrugs, 32: 53–68. aspects of liver regeneration. J Surg Res, 134: 238–251.
https://doi.org/10.1007/s40259-017-0258-x https://doi.org/10.1016/j.jss.2005.12.011
10. Peng W, Datta P, Ayan B, et al., 2017, 3D bioprinting for 23. Vellonen KS, Malinen M, Mannermaa E, et al., 2014, A
drug discovery and development in pharmaceutics. Acta critical assessment of in vitro tissue models for ADME and
Biomater, 57: 26–46. drug delivery. J Control Release, 190: 94–114.

Volume 9 Issue 2 (2023) 212 https://doi.org/10.18063/ijb.v9i2.663